Develops proprietary placenta-based cell therapy product candidates. Focuses on treating multiple inflammatory conditions using advanced cell therapies. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 44% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 12.5× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 1% of them.
Analysts' average target sits 917% above today's price.
An investor who bought at the very peak is down 95% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 44% a year on average.
Sales run at $1.0M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 18 buys and 2 sells. Management buying with its own money is usually read as a good sign.
A loss of $25.4M against $1.0M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.